Cardiola wins CE Mark recertification for m.pulse system

Swiss healthcare company Cardiola has received CE Mark recertification to market its m.pulse system for at-home use to treat chronic heart failure.

Cardiola’s m.pulse system, based on Muscular CounterPulsation (MCP) technology, has been recertified in Europe for treating chronic heart failure (CHF) as a nonsurgical, at-home therapy.

Battery-powered m.pulse, the size of a cell phone that the patient attaches to his belt for about 45 minutes per treatment, is synchronized to his cardiac cycle to stimulate the muscles of the calves and thighs to make them contract counter to the heart’s beating, said Cardiola.

This counterpulsation action results in increased blood flow to the heart muscle while decreasing the heart’s workload. Counterpulsation was previously only available in a clinical setting. Now, m.pulse is reportedly the world’s first and only device enabling CHF patients to receive MCP therapy at home.

The company has also appointed Walter Lange as COO and Josef Jungert as vice president of sales. In addition, the company has hired four direct sales representatives. As COO for Cardiola, Mr Lange brings in-depth production and supply chain management experience from his previous management positions. Prior to joining Cardiola, Mr Lange was head of product management at Egro Coffee Systems and Siemens Building Technologies.

Mr Jungert was an advisor to Cardiola prior to joining the company as vice president of sales. Prior to joining Cardiola, Mr Jungert was director of sales aesthetics for WaveLight.

Christof Lenz, CEO of Cardiola, said: We are extremely pleased that our m.pulse system has been cleared for marketing in Europe as a well-validated, affordable and non-surgical treatment alternative that patients themselves can perform in their own home.